BioSpace News Archive

Patients battling lung disease are frequently diagnosed through minimally invasive procedures that allow clinicians to perform vital ancillary tests on increasingly small specimens.

BELLUS Health Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, reported its financial and operating results for the first quarter ended March 31, 2020.

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company, today announced that it has commenced its previously-announced rights offering of up to 4,279,600 of units (the “Units,” and each, a “Unit”) at the Initial Price (as defined below) with an aggregate offering value of up to $30,000,000

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three months ended March 31, 2020. Results are presented in Canadian dollars unless otherwise noted. “The past two months have been especially trying for our residents, clients, frontline workers and their families,” said President and Chief Executive Officer, Dr. Michael Guerriere. “I want to express my heartfelt thanks to our team for their ongoing

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the RBC Capital Markets 2020 Global Healthcare Conference at 3:40 p.m. ET on Tuesday, May 19, 2020.

Innovent Biologics, Inc. (“Innovent” or “the Company”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic and other major diseases, today announced that clinical data on its ORIENT-2 study of TYVYT® (sintilimab injection), an innovative anti-PD-1 antibody co-developed with Eli Lilly and Company,

Arctic Vision, a clinical stage biotechnology company focusing on the development and commercialization of innovative ophthalmology therapies in China and Asia, announced the formation of its Scientific Advisory Board comprised of three world-class ophthalmologists from China, the United States and the United Kingdom.